Medpace Holdings, Inc. $MEDP Stock Holdings Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 375,033 shares of the company’s stock after buying an additional 60,883 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Medpace were worth $210,637,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Aptus Capital Advisors LLC acquired a new position in shares of Medpace in the 4th quarter worth approximately $253,000. FORA Capital LLC acquired a new position in shares of Medpace in the 4th quarter worth approximately $1,287,000. Kestra Advisory Services LLC boosted its position in Medpace by 44.1% during the 4th quarter. Kestra Advisory Services LLC now owns 1,085 shares of the company’s stock valued at $609,000 after purchasing an additional 332 shares during the period. Transamerica Financial Advisors LLC boosted its position in Medpace by 1,315.7% during the 4th quarter. Transamerica Financial Advisors LLC now owns 11,821 shares of the company’s stock valued at $6,639,000 after purchasing an additional 10,986 shares during the period. Finally, Marshall Wace LLP boosted its position in Medpace by 581.9% during the 4th quarter. Marshall Wace LLP now owns 44,951 shares of the company’s stock valued at $25,247,000 after purchasing an additional 38,359 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MEDP shares. Robert W. Baird reduced their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and reduced their price target for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Royal Bank Of Canada reduced their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Finally, Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $467.08.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is currently owned by insiders.

Medpace Stock Performance

NASDAQ:MEDP opened at $467.34 on Monday. The firm has a market capitalization of $13.35 billion, a price-to-earnings ratio of 29.37, a PEG ratio of 2.37 and a beta of 1.18. Medpace Holdings, Inc. has a 1-year low of $294.07 and a 1-year high of $628.92. The business’s fifty day moving average price is $456.43 and its 200 day moving average price is $503.84.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.